De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Par Drugs and Chemicals Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Par Drugs and Chemicals has been growing earnings at an average annual rate of 22.5%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 15.6% per year. Par Drugs and Chemicals's return on equity is 17%, and it has net margins of 15.3%.
Belangrijke informatie
22.5%
Groei van de winst
22.3%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 15.6% |
| Rendement op eigen vermogen | 17.0% |
| Nettomarge | 15.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13Opbrengsten en kosten
Hoe Par Drugs and Chemicals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 953 | 146 | 56 | 0 |
| 31 Mar 24 | 956 | 145 | 55 | 0 |
| 31 Dec 23 | 973 | 142 | 53 | 0 |
| 30 Sep 23 | 962 | 127 | 52 | 0 |
| 30 Jun 23 | 952 | 115 | 51 | 0 |
| 31 Mar 23 | 957 | 113 | 49 | 0 |
| 31 Dec 22 | 933 | 103 | 46 | 0 |
| 30 Sep 22 | 873 | 106 | 42 | 0 |
| 30 Jun 22 | 821 | 91 | 42 | 0 |
| 31 Mar 22 | 751 | 92 | 41 | 0 |
| 31 Dec 21 | 692 | 112 | 41 | 0 |
| 30 Sep 21 | 686 | 112 | 41 | 0 |
| 30 Jun 21 | 631 | 115 | 40 | 0 |
| 31 Mar 21 | 608 | 116 | 40 | 0 |
| 31 Dec 20 | 579 | 88 | 38 | 0 |
| 30 Sep 20 | 550 | 83 | 38 | 0 |
| 30 Jun 20 | 554 | 65 | 40 | 0 |
| 31 Mar 20 | 558 | 48 | 41 | 0 |
| 31 Dec 19 | 532 | 41 | 38 | 0 |
| 30 Sep 19 | 506 | 20 | 36 | 0 |
| 30 Jun 19 | 484 | 23 | 36 | 0 |
| 31 Mar 19 | 463 | 25 | 36 | 0 |
| 31 Mar 18 | 424 | 15 | 35 | 0 |
| 31 Mar 17 | 488 | 18 | 33 | 0 |
| 31 Mar 16 | 333 | 4 | 22 | 0 |
Kwaliteitswinsten: PAR has high quality earnings.
Groeiende winstmarge: PAR's current net profit margins (15.3%) are higher than last year (12.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PAR's earnings have grown significantly by 22.5% per year over the past 5 years.
Versnelling van de groei: PAR's earnings growth over the past year (26.6%) exceeds its 5-year average (22.5% per year).
Winst versus industrie: PAR earnings growth over the past year (26.6%) exceeded the Pharmaceuticals industry 19.2%.
Rendement op eigen vermogen
Hoge ROE: PAR's Return on Equity (17%) is considered low.